ANSES, UMR Virology 1161, Laboratoire de Sante Animale, Maisons-Alfort, France.
Vaccine. 2011 Mar 16;29(13):2495-502. doi: 10.1016/j.vaccine.2010.12.105. Epub 2011 Jan 21.
Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP(®) 8 (MERIAL) and BOVILIS(®) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines.
蓝舌病血清 8 型已成为欧盟的一个主要动物健康问题，欧盟成员国已就一项疫苗接种策略达成一致，该策略仅涉及灭活疫苗。在这项研究中，对自 2008 年以来在欧洲使用的两种针对蓝舌病病毒 8 型（BTV-8）的灭活疫苗的功效进行了评估，这两种疫苗是 BTVPUR ALSAP(®) 8（梅里亚）和 BOVILIS(®) BTV8（英特威/SP-AH），在实验条件下，用 BTV-8 田间分离株免疫和攻毒的山羊进行了评估。在攻毒前后进行了血清学、病毒学和临床检查。将 30 只山羊随机分为 3 组（A、B 和 C 组），其中 2 组（A 和 C）分别皮下接种两次，剂量为两种商业疫苗 BTVPUR ALSAP 8（A 组）或 BOVILIS BTV8（C 组）。A、C 和 B 组（B：对照组）的动物用含有 BTV-8 的强毒接种物进行攻毒。实验过程中发现，BTV-8 攻毒接种物被另一种 BTV 血清型污染。然而，结果表明，用 BTVPUR ALSAP 8 或 BOVILIS BTV8 进行两次注射对 BTV-8 攻毒具有显著的临床保护作用，并完全防止了所有接种动物的 BTV-8 血症。定性数据显示，这两种灭活疫苗诱导的体液反应的动力学和水平没有差异。
